Jennifer Michaelson

Jennifer Michaelson is an accomplished biotechnology executive with extensive experience in the fields of oncology and therapeutics. Currently serving as Chief Scientific Officer and Chief Development Officer at Cullinan Oncology, Jennifer has held prominent roles such as Vice President of Preclinical Research and Early Development, and Executive Program Leader at Jounce Therapeutics. Additionally, Jennifer has contributed to Third Rock Ventures as Head of Biologics for Celsius Therapeutics and served as a consultant for Jounce Therapeutics. Earlier in Jennifer’s career, significant positions at Biogen Idec included Principal Scientist and Senior Scientist. Jennifer’s educational background includes a medical degree from Harvard Medical School and a degree from Albert Einstein College of Medicine.